[Another case of Sertoli-Leydig cell ovarian tumor (arrhenoblastoma). Review of the literature].
In reporting another case of Sertoli-Leydig cell tumor (SLCT) treated by conservative management, the principal characteristics of these tumors are reviewed and a general review is made: SLCT (arrhenoblastomas) are rare endocrine tumors (1 p. cent of tumors of the ovary). They most frequently occur in young women, are unilateral in 98 p cent of cases, and are manifest after a long period by endocrine signs (75 p. cent of cases) whose most frequent combination is: amenorrhea-hirsutism-hoarse voice. They are classified in four histological types which have different prognoses. Their potential development varies and is variously assessed: these are tumors with a low incidence of malignancy (mean 18 p. cent). Under certain conditions, this permits the institution of conservative therapy conserving future fertility. Malignant types of tumors are treated in the same way as other malignant ovarian tumors: surgery is the main tool; radiotherapy is often insufficient and chemotherapy often provides remission more frequently than cure (80 p. cent 5 year survival).
Hocke
C
C
Clinique Gynécologique, Hôpital Saint-André, Bordeaux.
Constantopoulos
P
P
Berniac
E
E
Eudaric
M G
MG
Jouanelle
A
A
Brun
G
G
D000328:Adult; D005260:Female; D006801:Humans; D007985:Leydig Cells / Q000473:pathology*; D008297:Male; D012708:Sertoli Cells / Q000473:pathology*; D018310:Sertoli-Leydig Cell Tumor / Q000473:pathology* / Q000601:surgery
Un nouveau cas de tumeur ovarienne à cellules de Sertoli-Leydig (arrhénoblastome). Revue de la littérature.